Patents by Inventor Victor Giulio Matassa

Victor Giulio Matassa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9340547
    Abstract: New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: May 17, 2016
    Assignee: Almirall, S.A.
    Inventors: Francisco Javier Bernal Anchuela, Marta Carrascal Riera, Juan Francisco Caturla Javaloyes, Jordi Gracia Ferrer, Victor Giulio Matassa, Emma Terricabras Belart, Joan Taltavull Moll, Montserrat Erra Sola
  • Patent number: 9206183
    Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: December 8, 2015
    Assignee: ALMIRALL, S.A.
    Inventors: Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Paul Robert Eastwood, Jacob Gonzalez Rodrigues, Victor Giulio Matassa
  • Publication number: 20150118186
    Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: January 5, 2015
    Publication date: April 30, 2015
    Inventors: Jordi BACH TAÑA, Lluis Miquel PAGES SANTACANA, Joan TALTAVULL MOLL, Paul Robert EASTWOOD, Jacob GONZALEZ RODRIGUES, Victor GIULIO MATASSA
  • Publication number: 20150099752
    Abstract: New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
    Type: Application
    Filed: April 26, 2012
    Publication date: April 9, 2015
    Applicant: ALMIRALL, SA
    Inventors: Francisco Javier Bernal Anchuela, Marta Carrascal Riera, Juan Francisco Caturla Javaloyes, Jordi Gracia Ferrer, Victor Giulio Matassa, Emma Terricabras Belart, Joan Tal Tavul Moll, Montserat Eraa Sola
  • Publication number: 20140163033
    Abstract: New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
    Type: Application
    Filed: April 26, 2012
    Publication date: June 12, 2014
    Applicant: ALMIRALL, SA
    Inventors: Francisco Javier Bernal Anchuela, Marta Carrascal Riera, Juan Francisco Caturla Javaloyes, Jordi Gracia Ferrer, Victor Giulio Matassa, Emma Terricabras Belart, Joan Tal Tavul Moll, Montserat Eraa Sola
  • Publication number: 20140086870
    Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: February 18, 2011
    Publication date: March 27, 2014
    Inventors: Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Paul Robert Eastwood, Jacob Gonzalez Rodrigues, Victor Giulio Matassa
  • Publication number: 20130216498
    Abstract: New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: December 23, 2010
    Publication date: August 22, 2013
    Inventors: Paul Robert Eastwood, Jacob Gonzales Rodriguez, Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Victor Giulio Matassa
  • Publication number: 20130209400
    Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: February 18, 2011
    Publication date: August 15, 2013
    Inventors: Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Paul Robert Eastwood, Jacob Gonzalez Rodrigues, Victor Giulio Matassa
  • Patent number: 8450341
    Abstract: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: May 28, 2013
    Assignee: Almirall, S.A.
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Victor Giulio Matassa
  • Patent number: 8178679
    Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the ?2 adrenergic receptor.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: May 15, 2012
    Assignee: Almirall, S.A.
    Inventors: Victor Giulio Matassa, Carlos Puig Duran, Maria Prat Quiñones, Laia Sole Feu, Oriol Llera Soldevila
  • Publication number: 20110311485
    Abstract: The present disclosure relates to 1, 2, 4 oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors.
    Type: Application
    Filed: December 15, 2009
    Publication date: December 22, 2011
    Applicant: ALMIRALL S.A.
    Inventors: Victor Giulio Matassa, Nuria Aguilar Izquierdo, Marta Mir Cepeda, Marta Carrascal Riera, Silvia Fonquerna Pou, Aranzazu Cardus Figueras, Julio Cesar Castro Palomino Laria, Montserrat Erra Sola
  • Publication number: 20110046097
    Abstract: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 16, 2009
    Publication date: February 24, 2011
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Victor Giulio Matassa
  • Publication number: 20100324000
    Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the ?2 adrenergic receptor.
    Type: Application
    Filed: November 10, 2008
    Publication date: December 23, 2010
    Inventors: Victor Giulio Matassa, Carlos Puig Duran, Maria Prat Quiñones, Laia Sole Fue, Oriol Llera Soldevila
  • Publication number: 20080275086
    Abstract: The invention relates to compounds of formula (I) wherein Z, R1-7, X and n have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.
    Type: Application
    Filed: February 20, 2006
    Publication date: November 6, 2008
    Inventors: Paul John Edwards, Silvia Cerezo-Galvez, Meritxell Lopez-Canet, Victor Giulio Matassa, Claudia Rosenbaum, Christian Rummey, Sonja Nordhoff
  • Patent number: 7417064
    Abstract: There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, —CF3, —CN and —CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, nitro, acetyl, —CF3, —SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: August 26, 2008
    Assignee: Eli Lilly and Company
    Inventors: Serge Louis Boulet, Sandra Ann Filla, Peter Thaddeus Gallagher, Kevin John Hudziak, Anette Margareta Johansson, Rushad E. Karanjawala, John Joseph Masters, Victor Giulio Matassa, Brian Michael Mathes, Richard Edmund Rathmell, Maria Ann Whatton, Chad Nolan Wolfe
  • Patent number: 7410996
    Abstract: There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, —CF3, —CN and —CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0,
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: August 12, 2008
    Assignee: Eli Lilly and Company
    Inventors: Serge Louis Boulet, Sandra Ann Filla, Peter Thaddeus Gallagher, Kevin John Hudziak, Anette Margareta Johansson, Rushad E. Karanjawala, John Joseph Masters, Victor Giulio Matassa, Brian Michael Mathes, Richard Edmund Rathmell, Maria Ann Whatton, Chad Nolan Wolfe
  • Publication number: 20080176838
    Abstract: The invention relates to compounds of formula (I) wherein R1-9, Z, n, X, A, and Rb have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament for the treatment of type 2 diabetes mellitus, obesity and lipid disorders.
    Type: Application
    Filed: June 8, 2005
    Publication date: July 24, 2008
    Applicant: SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG
    Inventors: Paul John Edwards, Silvia Cerezo-Galvez, Achim Feurer, Oliver Hill, Meinolf Thiemann, Victor Giulio Matassa, Sonja Nordhoff, Meritxell Lopez-Canet
  • Patent number: 7119073
    Abstract: Compounds of formula (I), and pharmaceutically acceptable salts and esters thereof: (I); wherein Q, R2, X, Y and Z are as defined herein; are inhibitors of the hepatitis C virus (HCV) NS3 protease
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: October 10, 2006
    Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SpA
    Inventors: Stefania Colarusso, Cristina Gardelli, Benjamin Gerlach, Steven Harper, Uwe Koch, Victor Giulio Matassa, Ester Muraglia, Frank Narjes, Jesus Maria Ontoria Ontoria, Alessia Petrocchi, Simona Ponzi, Ian Stansfield, Vicenzo Summa
  • Publication number: 20040142876
    Abstract: Compounds of formula (I), and pharmaceutically acceptable salts and esters thereof: (I); wherein Q, R2, X, Y and Z are as defined herein; are inhibitors of the hepatitis C virus (HCV) NS3 protease.
    Type: Application
    Filed: March 3, 2004
    Publication date: July 22, 2004
    Inventors: Stefania Colarusso, Cristina Gardelli, Benjamin Gerlach, Steven Harper, Uwe Koch, Victor Giulio Matassa, Ester Muraglia, Frank Narjes, Jesus Maria Ontoria Ontoria, Alessia Petrocchi, Simona Ponzi, Ian Stansfield
  • Patent number: 6025374
    Abstract: A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: February 15, 2000
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Jose Luis Castro Pineiro, Caroline Henry, Victor Giulio Matassa, Austin John Reeve, Francine Sternfeld, Leslie Joseph Street